CytomX Q2 revenue falls to $1.4 million; net loss widens to $20.7 million
CytomX Therapeutics reported unaudited second-quarter 2026 results. Revenue fell to $1.4 million from $18.7 million a year earlier, and the company posted a net loss of $20.7 million, compared with a $154 thousand loss in the prior-year quarter, as operating expenses rose to $25.2 million. For shareholders, the shrinking revenue base and higher spending are partly offset by $330.3 million in cash and investments and a $37.0 million Regeneron payment received in July 2026.
Key points
- Revenue was $1.4 million for the quarter ended June 30, 2026, versus $18.7 million in Q2 2025; the company cited completed collaboration obligations with Bristol Myers Squibb and the Astellas collaboration concluding in Q2 2026.
- Net loss was $20.7 million, or $0.09 per share, versus a net loss of $154 thousand, or $0.00 per share, in Q2 2025.
- Operating expenses rose to $25.2 million from $19.9 million, led by research and development costs of $17.6 million.
- Cash, cash equivalents and investments were $330.3 million at June 30, 2026, down from $346.7 million at March 31, 2026; the company expects cash runway to at least the second half of 2028.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.